KALV - Company ID 0001348911
KalVista Pharmaceuticals, Inc. trades as KALV and has a market capitalization of $1.44 B, making it the #2383 largest US-listed company by market value. This page tracks KalVista Pharmaceuticals, Inc. through 834 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 8 fiscal years KalVista Pharmaceuticals, Inc.'s revenue grew from $2.13M to $50.00M, a compound annual growth rate of 48.3%. Net profit margin expanded from -1236.9% to -253.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| SCHEDULE 13D/A | - | 2026-05-21 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema | KalVista Pharmaceuticals
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio | KalVista Pharmaceuticals
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | KalVista Pharmaceuticals
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KalVista Pharmaceuticals
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference | KalVista Pharmaceuticals
The largest companies sharing KalVista Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
KalVista Pharmaceuticals, Inc. (KALV) has a market capitalization of $1.44 B as of 2026-07-09, ranking #2383 among US-listed companies.
In its latest fiscal year KalVista Pharmaceuticals, Inc. reported a net loss of $183.40M.